{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:19:23Z","timestamp":1783952363210,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22137008"],"award-info":[{"award-number":["22137008"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473809"],"award-info":[{"award-number":["82473809"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ejmech.2025.118412","type":"journal-article","created":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T07:50:49Z","timestamp":1764575449000},"page":"118412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Synthesis and discovery of guaianolide \u2010 eudesmanolide heterodimers as CDK2 inhibitors for the treatment of hepatocellular carcinoma"],"prefix":"10.1016","volume":"303","author":[{"given":"Tian-Ze","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Jiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Min","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Dan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Bao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Cui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1942-5725","authenticated-orcid":false,"given":"Ji-Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118412_bib1","doi-asserted-by":"crossref","first-page":"554","DOI":"10.21147\/j.issn.1000-9604.2022.06.02","article-title":"Burden of liver cancer: from epidemiology to prevention","volume":"34","author":"Li","year":"2022","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118412_bib2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","article-title":"Evolving therapeutic landscape of advanced hepatocellular carcinoma","volume":"20","author":"Yang","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejmech.2025.118412_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2024.100030","article-title":"Cell cycle dysregulation in cancer","volume":"77","author":"Glaviano","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2025.118412_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41392-024-02080-z","article-title":"Cyclin-dependent protein kinases and cell cycle regulation in biology and disease","volume":"10","author":"Pellarin","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2025.118412_bib5","first-page":"1913","article-title":"CDK inhibitors in cancer therapy, an overview of recent development","volume":"11","author":"Zhang","year":"2021","journal-title":"Am. J. Cancer Res."},{"issue":"8","key":"10.1016\/j.ejmech.2025.118412_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.116140","article-title":"Targeting CDK2 for cancer therapy","volume":"44","author":"Knudsen","year":"2025","journal-title":"Cell Rep."},{"key":"10.1016\/j.ejmech.2025.118412_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104324","article-title":"Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions","volume":"196","author":"Gerosa","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejmech.2025.118412_bib8","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1158\/2159-8290.CD-23-0954","article-title":"INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors","volume":"14","author":"Dietrich","year":"2024","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2025.118412_bib9","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1158\/0008-5472.CAN-24-2360","article-title":"Profiling the activity of the potent and highly selective CDK2 inhibitor BLU-222 reveals determinants of response in CCNE1-aberrant ovarian and endometrial tumors","volume":"85","author":"House","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118412_bib10","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2023.41.16_suppl.3010","article-title":"First-in-human phase 1\/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4\/6 inhibitor resistant HR+\/HER2- breast cancer","volume":"41","author":"Yap","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.ejmech.2025.118412_bib11","doi-asserted-by":"crossref","first-page":"18164","DOI":"10.1021\/acs.jmedchem.5c01478","article-title":"Discovery of AZD8421: a potent CDK2 inhibitor with selectivity against other CDK family members and the human kinome","volume":"68","author":"Ghosh","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118412_bib12","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/S0959-8049(22)01010-3","article-title":"Discovery of INCB123667, a potent and selective cyclin-dependent kinase 2 (CDK2) inhibitor for the treatment of cyclin E dysregulated cancers","volume":"174","author":"Wee","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2025.118412_bib13","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/j.apsb.2020.12.006","article-title":"New guaiane-type sesquiterpenoid dimers from Artemisia atrovirens and their antihepatoma activity","volume":"11","author":"Su","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.118412_bib14","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1002\/cjoc.202300242","article-title":"Novel germacrane-guaiane and eudesmane-guaiane sesquiterpenoid dmers from Artemisia princeps and their antihepatoma activity","volume":"41","author":"Su","year":"2023","journal-title":"Chin. J. Chem."},{"key":"10.1016\/j.ejmech.2025.118412_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.phytochem.2023.113714","article-title":"Thirteen undescribed sesquiterpenoid dimers from Artemisia princeps and their antihepatoma activity","volume":"211","author":"Su","year":"2023","journal-title":"Phytochemistry"},{"key":"10.1016\/j.ejmech.2025.118412_bib16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41392-022-01267-6","article-title":"Diverse structures and antihepatoma effect of sesquiterpenoid dimers from Artemisia eriopoda by AKT\/STAT signaling pathway","volume":"8","author":"He","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2025.118412_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.phytochem.2022.113299","article-title":"Artemidubolides A\u2212T, cytotoxic unreported guaiane-type sesquiterpenoid dimers against three hepatoma cell lines from Artemisia dubia","volume":"202","author":"Gao","year":"2022","journal-title":"Phytochemistry"},{"key":"10.1016\/j.ejmech.2025.118412_bib18","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/cjoc.202300166","article-title":"Guaiane-type sesquiterpenoid dimers from Artemisia zhongdianensis and antihepatoma carcinoma activity via the p38MAPK pathway","volume":"41","author":"Dong","year":"2023","journal-title":"Chin. J. Chem."},{"key":"10.1016\/j.ejmech.2025.118412_bib19","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3390\/plants10040677","article-title":"Biomimetic approaches to the synthesis of natural disesquiterpenoids: an update","volume":"10","author":"Caprioglio","year":"2021","journal-title":"Plants"},{"key":"10.1016\/j.ejmech.2025.118412_bib20","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1039\/C9NP00062C","article-title":"Natural disesquiterpenoids: an update","volume":"37","author":"Ma","year":"2020","journal-title":"Nat. Prod. Rep."},{"key":"10.1016\/j.ejmech.2025.118412_bib21","doi-asserted-by":"crossref","first-page":"8380","DOI":"10.1021\/acs.orglett.1c03120","article-title":"Biomimetic synthesis of lavandiolides H, I, and K and artematrolide F via Diels\u2013Alder reaction","volume":"23","author":"Li","year":"2021","journal-title":"Org. Lett."},{"key":"10.1016\/j.ejmech.2025.118412_bib22","doi-asserted-by":"crossref","first-page":"7322","DOI":"10.1021\/acs.joc.0c00705","article-title":"Synthesis of vlasouliolides: a pathway toward guaiane\u2013eudesmane C17\/C15 dimers by photochemical and Michael additions","volume":"85","author":"C\u00e1rdenas","year":"2020","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.ejmech.2025.118412_bib23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.phytol.2019.04.014","article-title":"Facile synthesis of anhydrojudaicin and 11,13-dehydroanhydrojudaicin, two eudesmanolide-skeleton lactones with potential allelopathic activity","volume":"31","author":"Zorrilla","year":"2019","journal-title":"Phytochem. Lett."},{"key":"10.1016\/j.ejmech.2025.118412_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113533","article-title":"Tuning the activity of known drugs via the introduction of halogen atoms, a case study of SERT ligands \u2013 fluoxetine and fluvoxamine","volume":"220","author":"Staro\u0144","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118412_bib25","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1002\/ddr.22087","article-title":"Design and synthesis of guaianolide-germacranolide heterodimers as novel anticancer agents against hepatocellular carcinoma","volume":"84","author":"Yan","year":"2023","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejmech.2025.118412_bib26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s13045-022-01347-8","article-title":"The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis","volume":"15","author":"Huang","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118412_bib27","first-page":"506","article-title":"A review of connectivity map and computational approaches in pharmacogenomics","volume":"19","author":"Musa","year":"2018","journal-title":"Briefings Bioinf."},{"key":"10.1016\/j.ejmech.2025.118412_bib28","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1093\/annonc\/mdq734","article-title":"A phase I pharmacokinetic and pharmacodynamic study of AT7519, a cyclin-dependent kinase inhibitor in patients with refractory solid tumors","volume":"22","author":"Mahadevan","year":"2011","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2025.118412_bib29","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1158\/1535-7163.MCT-08-0836","article-title":"AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts","volume":"8","author":"Byth","year":"2009","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.118412_bib30","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s00280-008-0921-5","article-title":"SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples","volume":"64","author":"Conroy","year":"2009","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118412_bib31","doi-asserted-by":"crossref","first-page":"9314","DOI":"10.3390\/ijms16059314","article-title":"Insights on structural characteristics and ligand binding mechanisms of CDK2","volume":"16","author":"Li","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118412_bib32","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1038\/s41467-022-30264-0","article-title":"Inhibition of the CDK2 and Cyclin A complex leads to autophagic degradation of CDK2 in cancer cells","volume":"13","author":"Zhang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118412_bib33","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1038\/sj.onc.1207446","article-title":"Cyclin A\/Cdk2 complexes regulate activation of Cdk1 and Cdc25 phosphatases in human cells","volume":"23","author":"Mitra","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118412_bib34","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/ncb2004","article-title":"Cdk2 suppresses cellular senescence induced by the c-myc oncogene","volume":"12","author":"Campaner","year":"2010","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118412_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118160","article-title":"Discovery of dimeric guaianolides with all carbon linkers as potential antihepatoma agents","volume":"300","author":"Li","year":"2025","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425011778?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425011778?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T04:52:27Z","timestamp":1781326347000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425011778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":35,"alternative-id":["S0223523425011778"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118412","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and discovery of guaianolide \u2010 eudesmanolide heterodimers as CDK2 inhibitors for the treatment of hepatocellular carcinoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118412","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118412"}}